Table 4.

Change in levels of analytes by tertiles of percent change in VO2max levels (mL/kg/min), compared with controls

Analyte andExercise onlyDiet + Exercise
change in VO2max,Baseline12 monthsAbs. changeBaseline12 monthsAbs. change
stratified by tertilesnGM (95% CI)nGM (95% CI)(%)aPbnGM (95% CI)nGM (95% CI)(%)aPb
Oxidized LDL (U/L)
Control8797.22 (89.33–105.8)8799.41 (91.97–107.4)2.19 (2.3)8797.22 (89.33–105.8)8799.41 (91.97–107.4)2.19 (2.3)
Increased <3.5%47107.1 (95.28–120.4)47110.2 (99.89–121.6)3.10 (2.9)0.495398.91 (91.64–106.8)5393.92 (86.31–102.2)−5.00 (−5.1)0.12
Increased ≥3.5%–14.3%3699.33 (87.75–112.4)3692.14 (80.41–105.6)−7.19 (−7.2)0.1932111.0 (100.0–123.1)3298.77 (88.97–109.7)−12.2 (−11.0)0.05
Increased ≥14.3%33100.0 (86.28–116.0)3399.59 (88.45–112.1)−0.43 (−0.4)0.843194.52 (82.98–107.7)3187.03 (76.16–99.44)−7.50 (−7.9)0.11
Ptrendc0.490.04
FOP (FI milliunits/mL)
Control8739.7 (35.1–44.9)8737.4 (35.0–39.9)−2.3 (−5.8)8737.7 (35.10–44.9)8737.4 (35.0–39.9)−2.3 (−5.8)
Increased <3.5%4740.2 (33.8.0–47.8)4736.0 (32.6–39.8)−4.2 (−10.5)0.575340.8 (35.2–47.3)5348.3 (40.1–58.1)7.4 (18.2)0.002
Increased ≥3.5%–14.3%3651.1 (37.2–70.4)3654.9 (37.8–79.7)3.7 (7.3)0.223240.9 (36.5–45.8)3248.2 (42.1-55.2)7.3 (17.9)0.0004
Increased ≥14.3%3343.5 (35.9–52.6)3339.8 (35.9–44.0)−3.7 (−8.5)0.693135.4 (31.6–39.7)3141.0 (38.0–44.2)5.6 (15.7)0.001
Ptrendc0.840.0002
F2-Isoprostanes (pg/mL)
Control8356.23 (50.71–62.36)8354.55 (49.15–60.54)−1.68 (−3.0)8356.23 (50.71–62.36)8354.55 (49.15–60.54)−1.68 (−3.0)
Increased <3.5%4567.56 (59.35–76.90)4562.27 (55.17–70.27)−5.29 (−7.8)0.134953.12 (44.22–63.81)4940.22 (34.14–47.38)−12.9 (−24.3)0.002
Increased ≥3.5%–14.3%3457.09 (48.18–67.64)3451.29 (43.81–60.05)−5.80 (−10.2)0.302855.27 (46.38–65.87)2844.76 (36.01–55.64)−10.5 (−19.0)0.03
Increased ≥14.3%2954.54 (44.64–66.65)2939.13 (30.10–50.85)−15.4 (−28.3)0.0013154.62 (46.10–64.72)3140.32 (34.36–47.31)−14.3 (−26.2)0.002
Ptrendc0.0030.0006
  • achange at 12 months from baseline.

  • bP value obtained from GEE model comparing the difference in change of the biomarkers from baseline to 12 months in intervention group versus control within tertiles of percent change in VO2max.

  • cP-value obtained from GEE model testing the linear trend in the change of the biomarkers from baseline to 12 months from control through all tertiles of percent change in VO2max. All models adjusted for age, baseline BMI (<30 kg/m2, ≥30 kg/m2), race/ethnicity (White, Black, and others), NSAID use, and statins use.